PLMI Blog

The mycobiome, referring to the fungal biota or communities within the microbiome ecosystem, is a critical yet often underappreciated component of the human microbiome (1). Within the gut, fungi such as Candida species and food-derived fungi play an essential role in modulating physiological and pathophysiological processes that maintain overall host homeostasis. These fungi also influence the composition and function of the broader and collective gut microbiome, having further modulatory implications on systemic health.

An imbalance in the gut mycobiome—induced by factors such as diet, stress, medications, and other environmental influences—can disrupt this delicate balance necessary for governing integral aspects of health, including systemic immunity and intestinal homeostasis. Such dysbiosis has been linked to the development of various systemic disorders, including inflammatory conditions, autoimmunity, and neuro autoimmunity, as well as neurodegenerative and neuropsychiatric disorders, underscoring the widespread impact of this fungal biota (2, 3).

The Diverse & Complex Microbiome Ecosystem

The gut microbiome is a vast and intricate ecosystem, home to an estimated 100 trillion microorganisms, including bacteria, archaea, viruses, and fungi (4). This diverse microbial community begins to colonize the gut at birth and evolves throughout life, influenced by genetics, lifestyle, environment, diet, and illness, while remaining highly sensitive to external stressors.

Recent advancements in sequencing technologies, such as PCR and next-generation sequencing, have transformed our understanding of the GI microbial inhabitants. Bacteria comprise 99% of the gut microbiota, with two dominant phyla—Bacteroidetes and Firmicutes—representing the majority. Key genera within Bacteroidetes include Bacteroides and Prevotella, while in Firmicutes, common genera include Lactobacillus, Bacillus, Clostridium, Enterococcus, and Ruminococcus (5, 6).

Fungal communities, or the gut mycobiome, constitute a smaller portion of the gut’s microbial diversity, making up only 0.01–0.1% of the total microbial population (7). Despite their relatively small abundance, these fungi play a crucial role in modulating host homeostasis, influencing both physiological and pathophysiological processes, and shaping the overall composition of the gut microbiome (8).

The Gut Mycobiome—An Integral Fungal Community

The gut mycobiome refers to the diverse fungal community inhabiting the gastrointestinal (GI) tract. While it comprises a much smaller proportion of the gut microbiome compared to bacteria, its role is far from insignificant. In fact, fungi are an essential component of the commensal flora across various body sites, including the skin, lungs, vagina, oral tract, and gut. In the digestive tract, fungal colonization begins shortly after birth and is influenced by factors like age, genetics, immunity, diet, medication, and the bacterial microbiome.

These fungi engage in intricate interactions with bacteria, the host’s immune system, and metabolic pathways, playing a critical role in maintaining GI health and overall systemic balance. Beneficial fungi contribute by producing essential metabolites, regulating immune responses, and preserving the integrity of the gut lining. However, when this delicate balance is disrupted, it can trigger a cascade of health issues, including inflammation, immune dysfunction, and metabolic disturbances.

Imbalances in the Gut Mycobiome – Fungal Dysbiosis

Several factors can contribute to an imbalance in the gut mycobiome, often referred to as fungal dysbiosis. Diet is one of the most influential factors. A diet rich in refined carbohydrates, sugars, saturated fats, and processed foods promotes the overgrowth of pathogenic fungi, such as Candida species, while simultaneously reducing the diversity of beneficial fungal populations (8). Findings suggest that a protein-rich diet is linked to a decreased abundance of Candida spp. and Methanobrevibacter bacteria in healthy individuals, while plant-based diets rich in fiber and tryptophan have also been found to confer favorable immune states for GI health.

Environmental toxins, including heavy metals, pesticides, and endocrine-disrupting chemicals, can also negatively impact the gut mycobiome by altering its composition and function.

Stress and inadequate sleep further exacerbate this imbalance by impeding gut barrier function and increasing systemic inflammation, creating an environment that fosters fungal overgrowth.

Medications, particularly antibiotics and antifungals, are another critical factor, as they can disrupt the delicate balance of the gut microbiome, including the mycobiome, by eliminating both harmful pathogens and beneficial microorganisms. This can potentially lead to imbalances or dysbiosis. Additionally, exposure to emulsifiers and other additives in processed foods can damage the gut’s mucosal lining, increasing intestinal permeability and allowing fungal components to interact with the immune system in ways that promote inflammation.

The Interplay Between the Immune System & the Gut Mycobiome

The gut mycobiome, the fungal component of the gut microbiome, plays a critical yet often underappreciated role in the complex interactions between the immune system and the gut environment, having important immunoregulatory functions.

This relationship underscores the broader picture of health and disease, where a delicate balance of microorganisms—including fungi—regulates immune responses and maintains overall health. Disruption of this balance, or dysbiosis, can have profound systemic implications, particularly in the context of inflammation, immune dysregulation, and the development of autoimmune conditions, as nearly 80% of the body’s immune system resides in the gut, making it pivotal for immune regulation and activity (9).

The gut mycobiome plays a crucial role in maintaining immune homeostasis, with beneficial fungi contributing to the production of key metabolites such as short-chain fatty acids (SCFAs). These SCFAs possess anti-inflammatory properties that help regulate immune responses and reinforce gut integrity. However, when the gut mycobiome becomes imbalanced—due to factors such as diet, stress, environmental toxins, or the use of certain medications—this balance can be disrupted (10). This dysbiosis often results in increased gut permeability, allowing fungal components like beta-glucans to cross the gut barrier and enter the bloodstream, triggering systemic inflammation and immune dysregulation.

Moreover, the gut mycobiome can impact the broader immune response by modulating the movement of immune cells from the gut into the central nervous system. When fungal species alter the peripheral immune system, this can lead to changes in the immune cell migration patterns, which may increase the risk of neuroinflammation and potentially accelerate the progression of neurodegenerative diseases. Therefore, the gut mycobiome is an important yet often overlooked player in the complex communication between the gut and the brain.

The immune system also plays a role in managing the gut mycobiome by recognizing and responding to fungal antigens (11). Using pattern recognition receptors, such as toll-like receptors, the immune system identifies fungal components and attempts to maintain a state of tolerance or defense. However, when this system is chronically overactivated—such as in cases of chronic inflammation or autoimmune conditions—it can lead to the overgrowth of pathogenic fungi. This exacerbates the imbalance of the gut mycobiome, creating a vicious cycle of immune dysregulation and fungal overgrowth. Immune interactions influence the composition and function of microbial species within the microbiome (12).

Disruptions in Gut Mycobiome & Immunity

A disrupted gut mycobiome can impair immune function in multiple ways. Reduced fungal diversity, for such, has been associated with a decrease in SCFA production and other metabolites critical for immune health. This diminishes the gut barrier’s integrity, heightening susceptibility to infections and contributing to systemic inflammation. Additionally, an overgrowth of certain fungal species can result in the production of mycotoxins, which directly suppress immune function and promote chronic disease states, further complicating the immune response. In fact, research highlights a connection between the gut mycobiome and skin health, further underscoring the role these humble, yet important, fungi have in modulating vast factors of health (13).

This intricate interplay between the immune system and the gut mycobiome underscores the significance of considering the mycobiome as part of a larger ecosystem, which includes fungi, bacteria, viruses, and host cells. When one component of this ecosystem is disrupted—such as the mycobiome—it can set off a cascade of effects that not only impair immune function but also induce inflammation and impede metabolic health, mood, and brain function. Indeed, imbalances in the gut mycobiome have been implicated in a range of health conditions, including metabolic disorders (14, 15), autoimmune disease (16-19), neurological conditions (20), and even cancer (21).

Emerging research connects dysbiosis of the gut mycobiota to a range of conditions, including schizophrenia, Alzheimer’s disease, autism spectrum disorders, bipolar disorder, and depression. Studies suggest that specific fungal populations, such as Candida and Saccharomyces, may impact neuroinflammation, gut permeability, and immune responses, thereby influencing mental health outcomes, as shown in a 2025 study published in The Journal of Frontiers of Cellular Neuroscience (22).

All of these conditions compellingly share an underlying feature of chronic inflammation, suggesting a common pathophysiological mechanism linked to dysbiosis in the collective gut microbiome and gut mycobiome (23).

A Dynamic & Imperative Relationship

The relationship between the immune system and the gut mycobiome is thus dynamic and reciprocal (11). An imbalanced mycobiome can compromise immune function, while immune dysregulation can exacerbate fungal dysbiosis. Recognizing and addressing this interplay is crucial for optimizing health and preventing the development of chronic diseases. By targeting the underlying factors that contribute to gut dysbiosis—such as poor diet, environmental toxins, stress, and medication use—personalized lifestyle medicine can help restore balance to the gut mycobiome, supporting immune function and overall well-being.

In summary, the gut mycobiome is not merely a passive resident within the gastrointestinal tract, but a vital player in the orchestration of immune responses, gut integrity, and metabolic health. Its disruption can have wide-reaching effects, contributing to a range of inflammatory and autoimmune conditions. Understanding the complex relationship between the gut mycobiome and the immune system is essential for addressing chronic diseases and promoting long-term health.

A future article will dive further into the health impacts of imbalance in the gut mycobiome, so stay tuned. To learn more, join us for this compelling free event, The Gut Mycobiome: A Central Figure in Health and Disease, occurring on June 10th from 5-7 PDT with Elroy Vojdani, MD, IFMCP, Aristo Vojdani, PhD, MSc, CL, and Jeffrey Bland, PhD. These experts will present compelling evidence linking disrupted mycobiomes to immune dysfunction through the release of fungal antigens, emphasizing the need for clinicians to incorporate both microbiome and mycobiome analysis into patient diagnosis and treatment for more targeted and effective therapeutic approaches. You won’t want to miss this informative and valuable event!

References:

1. Cui, L., Morris, A. & Ghedin, E. The human mycobiome in health and disease. Genome Med 5, 63 (2013). https://doi.org/10.1186/gm467
2. Yetgin, Ali, Exploring the Link Between the Gut Mycobiome and Neurological Disorders, Advanced Gut & Microbiome Research, 2024, 9965893, 11 pages, 2024. https://doi.org/10.1155/2024/9965893
3. Shah, Saumya et al. Alterations of the gut mycobiome in patients with MS
   eBioMedicine, Volume 71, 103557
4. Rodríguez JM, Murphy K, Stanton C, Ross RP, Kober OI, Juge N, Avershina E, Rudi K, Narbad A, Jenmalm MC, et al. The composition of the gut microbiota throughout life, with an emphasis on early life. Microb Ecol Health Dis. 2015. Feb 2;26. doi: 10.3402/mehd.v26.26050.
5. The Human Microbiome Project Consortium . Structure, function and diversity of the healthy human microbiome. 2012. June;486(7402):207–214.
6. Rinninella E, Raoul P, Cintoni M, Franceschi F, Miggiano GAD, Gasbarrini A, Mele MC. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. 2019. Jan 10;7(1):14. doi: 10.3390/microorganisms7010014.
7. Nash AK, Auchtung TA, Wong MC, Smith DP, Gesell JR, Ross MC, Stewart CJ, Metcalf GA, Muzny DM, Gibbs RA, et al. The gut mycobiome of the human microbiome project healthy cohort. 2017. Nov 25;5(1):153. doi: 10.1186/s40168-017-0373-4.
8. Zhang, Fen et al. The gut mycobiome in health, disease, and clinical association with the gut bacterial microbiome assembly. The Lancet Microbe, Volume 3, Issue 12, e969 – e983
9. Wiertsema SP, van Bergenhenegouwen J, Garssen J, Knippels LMJ. The Interplay between the Gut Microbiome and the Immune System in the Context of Infectious Diseases throughout Life and the Role of Nutrition in Optimizing Treatment Strategies. Nutrients. 2021 Mar 9;13(3):886. doi: 10.3390/nu13030886. PMID: 33803407; PMCID: PMC8001875.
10. Orestis Katsoulis, Oliver R Pitts, Aran Singanayagam, The airway mycobiome and interactions with immunity in health and chronic lung disease, Oxford Open Immunology, Volume 5, Issue 1, 2024, iqae009, https://doi.org/10.1093/oxfimm/iqae009
11. Li XV, Leonardi I, Iliev ID. Gut Mycobiota in Immunity and Inflammatory Disease. Immunity. 2019 Jun 18;50(6):1365-1379. doi: 10.1016/j.immuni.2019.05.023. PMID: 31216461; PMCID: PMC6585451.
12. Jensen O, Trujillo E, Hanson L, Ost KS. Controlling Candida: immune regulation of commensal fungi in the gut. Infect Immun. 2024 Sep 10;92(9):e0051623. doi: 10.1128/iai.00516-23. Epub 2024 Apr 22. PMID: 38647290; PMCID: PMC11385159.
13. Nguyen UT, Kalan LR. Forgotten fungi: the importance of the skin mycobiome. Curr Opin Microbiol. 2022 Dec;70:102235. doi: 10.1016/j.mib.2022.102235. Epub 2022 Nov 11. PMID: 36372041; PMCID: PMC10044452.
14. Mar Rodríguez, M ∙ Pérez, D ∙ Javier Chaves, F ∙ et al.Obesity changes the human gut mycobiome. Sci Rep. 2015; 5:14600
15. Lijie Wang, Kun Zhang, Yujiao Zeng, Yuting Luo, Jiayan Peng, Jing Zhang, Tingting Kuang, Gang Fan,Gut mycobiome and metabolic diseases: The known, the unknown, and the future,Pharmacological Research,Volume 193,2023,106807,ISSN 1043-6618, https://doi.org/10.1016/j.phrs.2023.106807.
16. Nelson, A ∙ Stewart, CJ ∙ Kennedy, NA ∙ et al.The impact of NOD2 genetic variants on the gut mycobiota in Crohn’s disease patients in remission and in individuals without gastrointestinal inflammation. J Crohn’s Colitis. 2021; 15:800-812
17. Liguori, G., Lamas, B., Richard, ML. et al.Fungal dysbiosis in mucosa-associated microbiota of Crohn’s disease patients. J Crohn’s Colitis. 2016; 10:296-305
18. Sokol, H ∙ Leducq, V., Aschard, H ∙ et al. Fungal microbiota dysbiosis in IBD. Gut. 2017; 66:1039-1048
19. Buttar J, Kon E, Lee A, Kaur G, Lunken G. Effect of diet on the gut mycobiome and potential implications in inflammatory bowel disease. Gut Microbes. 2024 Jan-Dec;16(1):2399360. doi: 10.1080/19490976.2024.2399360. Epub 2024 Sep 17. PMID: 39287010; PMCID: PMC11409510.
20. Zou, R., Wang, Y., Duan, M et al.Dysbiosis of gut fungal microbiota in children with autism spectrum disorders. J Autism Dev Disord. 2021; 51:267-275
21. Aykut, B., Pushalkar, S., Chen, R et al.The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL. Nature. 2019; 574:264-267
22. Hadrich I, Turki M, Chaari I, Abdelmoula B, Gargouri R, Khemakhem N, Elatoui D, Abid F, Kammoun S, Rekik M, Aloulou S, Sehli M, Mrad AB, Neji S, Feiguin FM, Aloulou J, Abdelmoula NB, Sellami H. Gut mycobiome and neuropsychiatric disorders: insights and therapeutic potential. Front Cell Neurosci. 2025 Jan 8;18:1495224. doi: 10.3389/fncel.2024.1495224. PMID: 39845646; PMCID: PMC11750820.
23. Tandon P, Abrams ND, Carrick DM, Chander P, Dwyer J, Fuldner R, Gannot G, Laughlin M, McKie G, PrabhuDas M, Singh A, Tsai SA, Vedamony MM, Wang C, Liu CH. Metabolic Regulation of Inflammation and Its Resolution: Current Status, Clinical Needs, Challenges, and Opportunities. J Immunol. 2021 Dec 1;207(11):2625-2630. doi: 10.4049/jimmunol.2100829. PMID: 34810268; PMCID: PMC9996538.